Cargando…

Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response

BACKGROUND: Interleukin-5 (IL-5) antibodies represent a promising therapeutic option for patients with severe eosinophilic asthma. To date, no official treatment response criteria exist. In this study, simple criteria for treatment response applicable to all asthma patients were used to evaluate cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drick, Nora, Seeliger, Benjamin, Welte, Tobias, Fuge, Jan, Suhling, Hendrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052600/ https://www.ncbi.nlm.nih.gov/pubmed/30021546 http://dx.doi.org/10.1186/s12890-018-0689-2

Ejemplares similares

Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD
por: Drick, Nora, et al.
Publicado: (2022)

Influence of anti-interleukin (IL)-5/anti-IL-5 receptor-α treatment on work productivity in patients with severe eosinophilic asthma
por: Drick, Nora, et al.
Publicado: (2023)

Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma
por: Franceschi, Elisa, et al.
Publicado: (2022)

The impact of anti-eosinophilic therapy on exercise capacity and inspiratory muscle strength in patients with severe asthma
por: Franceschi, Elisa, et al.
Publicado: (2023)

Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
por: Drick, Nora, et al.
Publicado: (2020)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
por: Kayser, Moritz Z, et al.
Publicado: (2021)

Relationship Between the Response to Antibody Therapy and Symptoms of Depression and Anxiety Disorders in Patients with Severe Asthma
por: Plank, Pia Maria, et al.
Publicado: (2023)

Chronic progressive pulmonary paracoccidioidomycosis in a female immigrant from Venezuela
por: Kayser, Moritz, et al.
Publicado: (2019)

Adherence is associated with a favorable outcome after lung transplantation
por: Bertram, Anna, et al.
Publicado: (2019)

Topical Nasal Anesthesia in Flexible Bronchoscopy – A Cross-Over Comparison between Two Devices
por: Fuehner, Thomas, et al.
Publicado: (2016)

Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
por: Bagnasco, Diego, et al.
Publicado: (2017)

Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights
por: Menzella, Francesco, et al.
Publicado: (2020)

Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
por: Bakakos, Agamemnon, et al.
Publicado: (2021)

Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma – der Biologics Asthma Response Score (BARS)
por: Milger, Katrin, et al.
Publicado: (2023)

Severe Eosinophilic Asthma
por: Bakakos, Agamemnon, et al.
Publicado: (2019)

Treating Acute Severe Eosinophilic Asthma with IL-5 Inhibitors in ICU
por: Barbarot, Nicolas, et al.
Publicado: (2022)

Changes in Type 2 Biomarkers After Anti-IL5 Treatment in Patients With Severe Eosinophilic Asthma
por: Jang, Jae-Hyuk, et al.
Publicado: (2020)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Involvement and Possible Role of Eosinophils in Asthma Exacerbation
por: Nakagome, Kazuyuki, et al.
Publicado: (2018)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019)

Eosinophilic bioactivities in severe asthma
por: Carr, Tara F., et al.
Publicado: (2016)

Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?
por: Van Hulst, Glenn, et al.
Publicado: (2021)

Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic “Overlap” severe asthma: Biological agent preference in atopic-eosinophilic severe asthma
por: Tepetam, Fatma Merve, et al.
Publicado: (2023)

Safety and efficacy of outpatient bronchoscopy in lung transplant recipients - a single centre analysis of 3,197 procedures
por: Rademacher, Jessica, et al.
Publicado: (2014)

IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma
por: Shimizu, Hideyasu, et al.
Publicado: (2021)

Conventional vs. Tablet Computer-Based Patient Education following Lung Transplantation – A Randomized Controlled Trial
por: Suhling, Hendrik, et al.
Publicado: (2014)

Anti‐interleukin 5 antibody is effective for not only severe asthma and eosinophilic pneumonia but also eosinophilic bronchiolitis
por: Tomyo, Fuminori, et al.
Publicado: (2018)

Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma
por: Park, Hae-Sim, et al.
Publicado: (2019)

Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma
por: Chia, Yen Lin, et al.
Publicado: (2019)

Diagnostic possibility of the combination of exhaled nitric oxide and blood eosinophil count for eosinophilic asthma
por: Li, Jiang-Hua, et al.
Publicado: (2021)

Targeting eosinophils: severe asthma and beyond
por: Caminati, Marco, et al.
Publicado: (2019)

Biological function of eosinophil extracellular traps in patients with severe eosinophilic asthma
por: Choi, Youngwoo, et al.
Publicado: (2018)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
por: Jackson, David J., et al.
Publicado: (2020)

Severe eosinophilic asthma in Chinese C‐BIOPRED asthma cohort
por: Zhang, Qingling, et al.
Publicado: (2022)

Severe asthma: anti-IgE or anti-IL-5?
por: Papathanassiou, Evgenia, et al.
Publicado: (2016)

Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma
por: Bagnasco, Diego, et al.
Publicado: (2018)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

COVID-19, Eosinophils, and Biologicals for Severe Asthma
por: Lombardi, Carlo, et al.
Publicado: (2022)

Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma
por: Nakamura, Yutaka, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_o2c05e2pcfbuqfe3lu1bttdmip